[go: up one dir, main page]

MX2021001564A - Diazabiciclooctanonas como inhibidores de serina beta-lactamasas. - Google Patents

Diazabiciclooctanonas como inhibidores de serina beta-lactamasas.

Info

Publication number
MX2021001564A
MX2021001564A MX2021001564A MX2021001564A MX2021001564A MX 2021001564 A MX2021001564 A MX 2021001564A MX 2021001564 A MX2021001564 A MX 2021001564A MX 2021001564 A MX2021001564 A MX 2021001564A MX 2021001564 A MX2021001564 A MX 2021001564A
Authority
MX
Mexico
Prior art keywords
diazabicyclooctanones
lactamases
inhibitors
useful
serine beta
Prior art date
Application number
MX2021001564A
Other languages
English (en)
Inventor
David Thomas Davies
Simon Leiris
Original Assignee
Antabio Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18290093.6A external-priority patent/EP3608318A1/en
Priority claimed from EP18213635.8A external-priority patent/EP3670512A1/en
Application filed by Antabio Sas filed Critical Antabio Sas
Publication of MX2021001564A publication Critical patent/MX2021001564A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a un compuesto que es una diazabiciclooctanona de la Fórmula (I) o una sal farmacéuticamente aceptable del mismo: (Ver Fòrmula I), donde R es como se define en este documento. Los compuestos son útiles en el tratamiento de la infección bacteriana, en particular son útiles en reducir la resistencia bacteriana a los antibióticos. También son útiles en el tratamiento de bacterias que expresan enzimas serina-ß- lactamasa, en combinación con antibióticos.
MX2021001564A 2018-08-09 2019-08-08 Diazabiciclooctanonas como inhibidores de serina beta-lactamasas. MX2021001564A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18290093.6A EP3608318A1 (en) 2018-08-09 2018-08-09 Diaazabicyclooctanone derivatives as antibacterials
EP18213635.8A EP3670512A1 (en) 2018-12-18 2018-12-18 Diazabicyclooctanones as inhibitors of serine beta-lactamases
PCT/EP2019/071370 WO2020030761A1 (en) 2018-08-09 2019-08-08 Diazabicyclooctanones as inhibitors of serine beta-lactamases

Publications (1)

Publication Number Publication Date
MX2021001564A true MX2021001564A (es) 2021-05-12

Family

ID=67667824

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001564A MX2021001564A (es) 2018-08-09 2019-08-08 Diazabiciclooctanonas como inhibidores de serina beta-lactamasas.

Country Status (24)

Country Link
US (1) US12378244B2 (es)
EP (2) EP3833665B1 (es)
JP (1) JP7429988B2 (es)
KR (1) KR102790878B1 (es)
CN (2) CN117384155A (es)
AU (1) AU2019318115B2 (es)
BR (1) BR112021002311A2 (es)
CA (1) CA3110111A1 (es)
DK (1) DK3833665T3 (es)
ES (1) ES2960952T3 (es)
FI (1) FI3833665T3 (es)
HR (1) HRP20231228T1 (es)
HU (1) HUE063324T2 (es)
IL (1) IL280770B2 (es)
LT (1) LT3833665T (es)
MX (1) MX2021001564A (es)
PL (1) PL3833665T3 (es)
RS (1) RS64679B1 (es)
SG (1) SG11202101255UA (es)
SI (1) SI3833665T1 (es)
SM (1) SMT202300354T1 (es)
TW (1) TWI764030B (es)
WO (1) WO2020030761A1 (es)
ZA (1) ZA202100906B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111943950B (zh) * 2020-09-10 2022-03-29 山东安信制药有限公司 一种瑞来巴坦的制备方法
EP4146651A4 (en) * 2021-05-07 2024-06-05 Ningxia Academy of Agriculture and Forestry Sciences SULFONYLAMIDINE SUBSTITUTED COMPOUNDS AND THEIR USE AS BETA-LACTAMASE INHIBITORS
CN115448920B (zh) * 2022-10-14 2025-01-03 广州楷石医药有限公司 一种β-内酰胺酶抑制剂及其应用
GB202306833D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
GB202306826D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
CN117700415B (zh) * 2024-02-06 2024-04-30 成都四面体药物研究有限公司 含脲双环化合物、其用途、其制备的药物、其联合用药物及其复方制剂
WO2025215253A1 (en) 2024-04-12 2025-10-16 Antabio Sas Dosing regimen comprising (2r,5r)-2-fluoro-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulphate and a beta-lactam antibiotic

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0678095A1 (en) 1993-11-06 1995-10-25 Taiho Pharmaceutical Co., Ltd. Crystalline penicillin derivative, and its production and use
US6979735B1 (en) 1999-04-01 2005-12-27 Dsm N.V. Agglomerates by crystallization
NZ517663A (en) 1999-08-16 2006-02-24 Revaax Pharmaceuticals Llc Neurotherapeutic clavulanate composition and method
US20030148324A1 (en) 2001-02-02 2003-08-07 Edouard Bingen Polynucleotides which are of nature B2/D+ A- and which are isolated from E. coli, and biological uses of these polynucleotides and of their polypeptides
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
SE0102058D0 (sv) 2001-06-08 2001-06-08 Astrazeneca Ab New Salts II
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
DE10218328A1 (de) 2002-03-05 2003-09-25 Humboldt Uni Zu Berlin Medizin Mittel zur präventiven Therapie nach akutem Schlaganfall
EP1342784A1 (en) 2002-03-06 2003-09-10 Mutabilis S.A. ExPEC-specific proteins, genes encoding them and uses thereof
WO2003078654A1 (en) 2002-03-13 2003-09-25 Creighton University Device and method for detecting antibiotic inactivating enzymes
FR2842210B1 (fr) 2002-07-09 2012-12-14 Mutabilis Determinants de pathogenicite utilisables comme cibles pour l'elaboration de moyens de prevention et de controle d'infections bacteriennes et/ou de la dissemination systemique
US6928313B2 (en) 2003-01-27 2005-08-09 Cardiac Pacemakers, Inc. System and method for accessing the coronary sinus to facilitate insertion of pacing leads
JP2007522150A (ja) 2004-02-05 2007-08-09 ザ ジェネラル ホスピタル コーポレーション しわ治療のためのプロテアーゼ阻害剤
EP1580195A1 (en) 2004-03-26 2005-09-28 Mutabilis SA Compositions of polypeptides specific to pathogenic ExPEC E. coli strains and their use as vaccines and in immunotherapy
PT1841432E (pt) 2004-12-02 2010-10-25 Venus Remedies Ltd Composições para combater a resistência aos antibióticos mediada pela beta-lactamase usando inibidores da betalactamase úteis para injecção
EP1669365A1 (en) 2004-12-03 2006-06-14 Mutabilis SA Method for preparing enzymatic substrate analogs as inhibitors of bacterial heptosyl-transferases
JP2008524204A (ja) 2004-12-17 2008-07-10 ヴィーナス・レメディーズ・リミテッド 感染の処置に全面的解決を与えるための抗生物質の組合せ
CA2641605A1 (en) 2006-02-09 2007-08-23 Schering Corporation Pharmaceutical formulations
JP2009526062A (ja) 2006-02-09 2009-07-16 シェーリング コーポレイション 薬学的処方物
EP1845087A1 (en) 2006-04-14 2007-10-17 Mutabilis SA Hydroxyphenyl derivatives and biological applications thereof
US20100261618A1 (en) 2006-06-19 2010-10-14 Sonia Escaich Identification of genes implicated in the virulence of streptococcus agalactiae
EP2104671A2 (en) 2006-09-25 2009-09-30 Mutabilis SA Substituted heterocyclylcarbonylamino-acetic-acid-derivatives as inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors
EP1972629A1 (en) 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
WO2009008006A2 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
AU2009206119C1 (en) 2008-01-18 2016-05-26 Merck Sharp & Dohme Llc Beta-lactamase inhibitors
EP2141164A1 (en) 2008-07-01 2010-01-06 Mutabilis New 1,2,4-triazine derivatives and biological applications thereof
BRPI0920180B1 (pt) 2008-10-14 2021-10-26 Entasis Therapeutics Limited Compostos herecíclicos substituídos, uso dos mesmos e composiçâo farmacêutica compreendendo os ditos compostos
US20110020272A1 (en) 2009-07-24 2011-01-27 Ulrich Schubert Combination therapy for treating hepatitis viral infection
BR112012010270A2 (pt) 2009-10-30 2016-11-29 Biogenic Innovations Llc mentisulfonilmetano (msm) para tratamento de micro-organismos resistentes a fármaco
US20130164338A1 (en) 2010-08-30 2013-06-27 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
EP2646451A2 (en) 2010-12-01 2013-10-09 Laboratoire Biodim Heptose derivatives for use in the treatment of bacterial infections
SI2657234T1 (sl) 2010-12-22 2017-06-30 Meiji Seika Pharma Co., Ltd. Derivat optično-aktivnega diazabiciklooktana in metoda za njegovo izdelavo
TWI565706B (zh) 2011-06-17 2017-01-11 阿斯特捷利康公司 用於製備包括反－７－酮基－６－（磺酸氧基）－１，６－二氮雜雙環［３，２，１］辛烷－２－甲醯胺之雜環化合物及其鹽類之方法
JP5808860B2 (ja) 2011-07-26 2015-11-10 ウォックハート リミテッド スルバクタム及びベータ−ラクタマーゼインヒビターを含む医薬組成物
ES2606059T3 (es) * 2011-08-30 2017-03-17 Wockhardt Limited Derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona y su uso en el tratamiento de infecciones bacterianas
WO2013038330A1 (en) 2011-09-13 2013-03-21 Wockhardt Limited Nitrogen containing compounds and their use
US20130108683A1 (en) 2011-10-25 2013-05-02 Biomimetic Therapeutics, Inc. Compositions and methods for treating partial and full thickness wounds and injuries
WO2013062994A1 (en) 2011-10-25 2013-05-02 Biomimetic Therapeutics, Inc. Compositions and methods for treating full thickness burn injuries
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
WO2013122888A2 (en) 2012-02-15 2013-08-22 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
SG11201406123TA (en) 2012-03-30 2014-10-30 Cubist Pharm Inc 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE β-LACTAMASE INHIBITORS
WO2013149136A1 (en) 2012-03-30 2013-10-03 Cubist Pharmaceuticals, Inc. ISOXAZOLE β-LACTAMASE INHIBITORS
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
PT2857401T (pt) 2012-05-30 2019-11-19 Meiji Seika Pharma Co Ltd Novo inibidor de β-lactamase e método para a produção do mesmo
WO2014033560A1 (en) 2012-08-25 2014-03-06 Wockhardt Limited 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
CA2886402A1 (en) 2012-09-27 2014-04-03 Cubist Pharmaceuticals, Inc. Tazobactam arginine antibiotic compositions
EP2725029A1 (en) 2012-10-29 2014-04-30 Laboratoire Biodim New antibacterial compounds and biological applications thereof
UA111925C2 (uk) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
RU2676482C2 (ru) 2013-01-14 2018-12-29 Вокхардт Лимитед Композиции и способы лечения бактериальных инфекций
US8889671B2 (en) 2013-01-23 2014-11-18 Astrazeneca Ab Compounds and methods for treating bacterial infections
EP2953626A1 (en) 2013-02-06 2015-12-16 Astrazeneca AB Combination therapy for the treatment of nosocomial pneumonia
WO2014141132A1 (en) 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
ES2495666B1 (es) 2013-03-15 2015-08-10 Laboratoris Sanifit, S.L. Uso de derivados con enlaces c-o-p en pacientes con fallo renal
US9364490B2 (en) 2013-03-15 2016-06-14 Laboratoris Sanifit, S.L. Use of derivatives containing C—O—P bonds in patients with kidney failure
GB201310542D0 (en) 2013-06-13 2013-07-31 Antabio Sas Compounds
EP2821104A1 (en) 2013-07-05 2015-01-07 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
CN106132411A (zh) 2013-10-22 2016-11-16 沃克哈特有限公司 包含抗菌剂的药物组合物
EP3097105B1 (en) 2014-01-21 2018-12-19 Wockhardt Limited 2-(1,3,4-oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo[3.2.1]octane derivatives and their use as antibacterial agents
KR20160115946A (ko) 2014-02-03 2016-10-06 욱크하르트 리미티드 (2s,5r)-1,6-다이아자-바이사이클로[3.2.1]옥테인-2-카보나이트릴-7-옥소-6-(설포옥시)-모노 소듐 염의 제조 공정
EP3107539A1 (en) 2014-02-20 2016-12-28 Wockhardt Limited Pharmaceutical combinations comprising antibacterial agents
EP2913330A1 (en) 2014-02-27 2015-09-02 Laboratoire Biodim Condensed derivatives of imidazole useful as pharmaceuticals
CN106794250A (zh) 2014-03-14 2017-05-31 沃克哈特有限公司 包含抗菌剂的药物组合物
JP6153674B2 (ja) 2014-03-24 2017-06-28 ノバルティス アーゲー 細菌感染を治療するためのモノバクタム有機化合物
US20170027917A1 (en) 2014-04-18 2017-02-02 Wockhardt Limited Pharmaceutical compositions comprising antibacterial agents
US10857138B2 (en) 2014-04-18 2020-12-08 Wockhardt Limited Pharmaceutical compositions comprising antibacterial agents
MX365261B (es) 2014-05-29 2019-05-27 Entasis Therapeutics Ltd Compuestos heteroaromaticos espirociclicos, fusionados para el tratamiento de infecciones bacterianas.
US20150361108A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
LT3221313T (lt) 2014-11-17 2019-03-25 Entasis Therapeutics Limited Derinių terapija, skirta atsparių bakterinių infekcijų gydymui
GB2533136A (en) 2014-12-11 2016-06-15 Antabio Sas Compounds
WO2016116788A1 (en) 2015-01-24 2016-07-28 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2016128867A1 (en) 2015-02-12 2016-08-18 Wockhardt Limited Azetidinone containing compounds and their use in treatment of bacterial infections
RU2715058C2 (ru) 2015-03-31 2020-02-25 Мутабилис Гетероциклические соединения и их применение для предупреждения или лечения бактериальных инфекций
CA2980085A1 (en) 2015-03-31 2016-10-06 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections
RU2714197C2 (ru) 2015-04-03 2020-02-13 Мутабилис Гетероциклические соединения и их применение для предупреждения или лечения бактериальных инфекций
US10183943B2 (en) 2015-05-07 2019-01-22 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
WO2017002086A1 (en) 2015-07-02 2017-01-05 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2017002083A1 (en) 2015-07-02 2017-01-05 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2017002089A1 (en) 2015-07-02 2017-01-05 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2017002087A1 (en) 2015-07-02 2017-01-05 Wockhardtlimited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
CN106467705B (zh) 2015-08-17 2019-02-22 3M创新有限公司 防滑液、防滑件及其制备方法
WO2017037607A1 (en) 2015-09-01 2017-03-09 Wockhardt Limited (aminomethylidene)amino-substituted (2s,5r)-6-(sulfonyl)-7-oxo-1,6-diazabicyclo[3.2.1 ]octane-2-carboxamide derivatives with antibacterial activity
WO2017096472A1 (en) 2015-12-10 2017-06-15 Naeja-Rgm Pharmaceuticals Inc. Cephem compounds, their production and use
EP3184529A1 (en) 2015-12-23 2017-06-28 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
WO2017156239A1 (en) 2016-03-11 2017-09-14 California Institute Of Technology Compositions and methods for acylating lactams
WO2017203266A1 (en) 2016-05-25 2017-11-30 Entasis Therapeutics Limited Combination therapy for treatment of resistant bacterial infections
WO2017216765A1 (en) 2016-06-17 2017-12-21 Wockhardt Limited Antibacterial compositions
MX392515B (es) 2016-09-16 2025-03-24 Entasis Therapeutics Ltd Compuestos inhibidores de beta-lactamasa
EP3300736B1 (en) 2016-09-30 2021-05-05 Mutabilis Composition comprising antibiotic compound and an heterocyclic compound and their use in preventing or treating bacterial infections
WO2018129008A1 (en) 2017-01-04 2018-07-12 Entasis Therapeutics Inc. Compounds and methods for treating bacterial infections
EP3357924A1 (en) 2017-02-06 2018-08-08 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections
JP2020506198A (ja) 2017-02-06 2020-02-27 ミュタビリスＭｕｔａｂｉｌｉｓ 新規な複素環化合物と、細菌感染症の予防または治療におけるその利用
MA48743A (fr) 2017-05-08 2020-04-08 Entasis Therapeutics Inc Composés et méthodes de traitement d'infections bactériennes
MA49623A (fr) 2017-07-21 2021-03-17 Antabio Sas Composés chimiques
CN107501265B (zh) 2017-10-09 2019-05-28 台州职业技术学院 一种7-氧代-二氮杂二环[3,2,1]辛烷衍生化合物及其制备方法和应用
WO2019093450A1 (ja) 2017-11-10 2019-05-16 塩野義製薬株式会社 ジアザビシクロオクタン誘導体
EP3572411A1 (en) 2018-05-21 2019-11-27 Antabio SAS Thiazole derivatives as metallo-beta-lactamase inhibitors
EP3604309A1 (en) 2018-07-30 2020-02-05 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EP3604315A1 (en) 2018-07-30 2020-02-05 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
US11905286B2 (en) * 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases

Also Published As

Publication number Publication date
IL280770A (en) 2021-04-29
TWI764030B (zh) 2022-05-11
IL280770B1 (en) 2024-01-01
LT3833665T (lt) 2023-11-10
ZA202100906B (en) 2023-07-26
SG11202101255UA (en) 2021-03-30
EP3833665B1 (en) 2023-07-19
SI3833665T1 (sl) 2023-12-29
KR20210055701A (ko) 2021-05-17
CN117384155A (zh) 2024-01-12
DK3833665T3 (da) 2023-10-09
HRP20231228T1 (hr) 2024-01-19
CN111954671B (zh) 2023-09-01
RS64679B1 (sr) 2023-11-30
US20240391919A1 (en) 2024-11-28
IL280770B2 (en) 2024-05-01
EP4272831A3 (en) 2024-02-21
JP7429988B2 (ja) 2024-02-09
JP2021534095A (ja) 2021-12-09
WO2020030761A1 (en) 2020-02-13
HUE063324T2 (hu) 2024-01-28
CA3110111A1 (en) 2020-02-13
ES2960952T3 (es) 2024-03-07
PL3833665T3 (pl) 2023-12-27
CN111954671A (zh) 2020-11-17
TW202019929A (zh) 2020-06-01
EP3833665A1 (en) 2021-06-16
BR112021002311A2 (pt) 2021-05-04
AU2019318115B2 (en) 2024-04-18
EP4272831A2 (en) 2023-11-08
KR102790878B1 (ko) 2025-04-02
SMT202300354T1 (it) 2023-11-13
AU2019318115A1 (en) 2021-03-11
FI3833665T3 (fi) 2023-10-09
US12378244B2 (en) 2025-08-05

Similar Documents

Publication Publication Date Title
MX2021001564A (es) Diazabiciclooctanonas como inhibidores de serina beta-lactamasas.
PH12017502418A1 (en) 3-tetrazolyl-benzene-1,2-disulfonamide derivatives as metallo-beta-lactamase inhibitors
TN2014000417A1 (en) Heterobicyclic compounds as beta-lactamase inhibitors
MX385507B (es) Compuestos inhibidores de beta-lactamasa
MX2018010878A (es) Compuestos de aril-monobactam biciclicos y metodos de uso de los mismos para el tratamiento de infecciones bacterianas.
PH12020550107A1 (en) Chromane monobactam compounds for the treatment of bacterial infections
WO2018208985A3 (en) Antibacterial compounds
NZ593111A (en) Antibacterial compounds
PH12017500852A1 (en) Combination therapy for treatment of resistant bacterial infections
MX2021003084A (es) Compuestos antibacterianos.
MX2020000576A (es) Compuestos quimicos.
ZA202006612B (en) Antibacterial compounds
NZ594675A (en) Actagardine derivatives
EP4268897A3 (en) Minocycline compounds for biodefense
MX2019006768A (es) Peptidos antimicrobianos.
NZ758200A (en) Compounds and methods for treating bacterial infections
MA32375B1 (fr) Derives de 5-hydroxymethyl-oxazolidine-2-one pour le traitement de maladies intestinales bacteriennes
NZ706734A (en) Pharmaceutical compositions useful for the treatment or control of bacterial infections
ZA202309204B (en) Lactivicin compounds, their preparation and use as antibacterial agents
MX2022006109A (es) Derivados 1-aminosulfonil-2-carboxipirrol como inhibidores de metalo-beta-lactamasa.
MX2021003485A (es) Derivados de indano para uso en el tratamiento de infeccion bacteriana.
NZ737820A (en) Mannose derivatives for treating bacterial infections
SG166798A1 (en) Quinolone derivatives as antibacterial agents
EA202190444A1 (ru) Диазабициклооктаноны в качестве ингибиторов сериновых бета-лактамаз
EA202090357A1 (ru) Химические соединения